USDA-approved Feline Leukemia Virus
Immunodeficiency Virus Treatment
Murrieta, CA (December 29, 2011)…Dr.
Terry Beardsley, founder and principal clinical
researcher behind LTCI, the first USDA-approved
treatment for Feline Leukemia Virus (FeLV) and
Feline Immunodeficiency Virus (FIV) announced the
launch of a
new website and a simplified process for
veterinarians to order Lymphocyte T-Cell
Immunomodulator (LTCI) to treat their patients.
FeLV and FIV infections are two of the most common
and fatal feline diseases worldwide. Infections can
cause severe immune suppression and anemia and
result in increased risk of other infections. LTCI
is the first, and only, approved treatment aid in
the United States for cats suffering from FeLV and
There was no effective treatment of these diseases
or their symptoms until LTCI was granted a
conditional license by the USDA. Veterinarians could
only prescribe palliative care, isolation, and
ultimately, euthanasia. LTCI is able to enhance the
immune status of FeLV/FIV-infected cats with a
corresponding, significant improvement in clinical
symptoms. The therapeutic effects appear to be
long-lasting, and without any side effects.
T-Cyte Therapeutics’ website, www.TCyte.com, and new
online capabilities mean that both pet owners and
veterinarians can keep up-to-date on advances in the
care and treatment of FeLV and FIV, and animal
clinics can directly order and manage timely
shipments of LTCI, particularly in cases of
critically ill patients. The site also features
educational and product information on retroviral
health care and plans to add a searchable database
of veterinary clinics across the country that offer
LTCI for cats with FeLV and/or FIV.
“We’ve worked hard to build a website that
streamlines access to pertinent, practical and
accurate information regarding the treatment of
these heretofore untreatable diseases [FeLV and FIV]
and give veterinarians direct source access to LTCI.
www.TCyte.com will be an efficient, factual resource
for both pet owners and veterinarians,” said Dr.
Beardsley. “The site will make it easier for pet
owners to locate local veterinarians who treat cats
suffering from these terrible maladies; the website
will be a one-stop data source to aid in the
treatment of FeLV and FIV.”
About T-Cyte Therapeutics:
T-Cyte Therapeutics (www.TCyte.com)
dedicated to providing safe, effective,
science-based products that enhance the health of
animals, allowing owners
enjoy their longer-lived and healthier animals.
worldwide medical community's scramble to find a
the deadly HIV/AIDS pandemic, scientists used the
Virus (FeLV) and
Immunodeficiency Virus (FIV) as research models for
the human diseases. Advances in understanding the
immune system were moving
Even before this all-out race, Dr. Terry Beardsley,
as a graduate researcher specializing in immunology
at Baylor College of Medicine, had set out to
discover a biological treatment pathway that
emulated the body's own, natural defense processes,
a discovery that could reverse the fatal effects of
severe combined immune deficiency disease (SCID).
This work resulted in a better understanding of bone
marrow transplantation and the function of the
While a faculty member at UCLA, Dr. Beardsley
demonstrated, that retrovirus infection alters the
structure of the thymus gland and its ability to
produce mature functional T-Cells; that retrovirus
infection of thymic epithelial cells caused
defective T-Cell development, leading to immune
deficiency and/or leukemia. He ultimately proved
that the destruction of thymic epithelium is a major
contributor to failure of immune regeneration in
At the University of California, Dr. Beardsley
refined this cellular theory and was the first to
clone thymic epithelial cells, successfully
identifying and describing one of the
immunoregulatory proteins involved in the process
and the type of cells that produced it. That
peptides extracted from thymus gland cells could
control the immune system's response to viral
attack, culminated in a landmark publication of Dr.
Beardsley's research findings in The Proceedings of
the National Academy of Science. With anti-HIV drug
cocktails promising hope for HIV/AIDS patients, Dr.
Beardsley studies had shown that his Lymphocyte
T-cell Immunomodulator (LTCI) molecule could be used
as a therapy for the treatment of immuno-compromised
cats. He formed
T-Cyte Therapeutics, Inc.
to develop LTCI to treat the devastating effects of
FeLV and FIV viruses in cats.